Methods of inhibiting solid tumor growth by administering GPR49 antibodies
Described herein are antibodies against GPR49 and uses of such antibodies. Various aspects relate to monoclonal, humanized, or fully human antibodies against GPR49, hybridomas or other cell lines expressing such antibodies, nucleic acids and vectors comprising nucleic acids encoding for such antibodies, and methods of treating cancer with such antibodies.
1. A method of inhibiting growth of a solid tumor in a mammal, comprising administering to the mammal a therapeutic amount of a monoclonal antibody that binds to G-Protein Coupled Receptor 49 (GPR49) polypeptide, wherein the GPR49 polypeptide has an amino acid sequence of SEQ ID NO: 1 and the therapeutic amount is sufficient to inhibit growth of the tumor, and wherein the antibody has antitumor activity against human tumor cells in vivo, and the antibody has activity capable of causing internalization of GPR49 in cells contacted with the antibody.
2. The method of claim 1 , wherein the therapeutic amount of the antibody is sufficient to reduce the rate of tumor growth in the mammal.
3. The method of claim 2 , wherein the reduced rate of tumor growth comprises a reduced rate in the increase of tumor volume.
4. The method of claim 2 , wherein the therapeutic amount of the antibody is sufficient to increase survival of the mammal compared to control.
5. The method of claim 1 , wherein the antibody is an IgG-class antibody.
6. The method of claim 2 , wherein the antibody is an IgG1-class antibody.
7. The method of claim 2 , wherein the antibody is a mouse antibody.
8. The method of claim 1 , wherein the monoclonal antibody binds to GPR49 polypeptide with a K d in the range of 10×10 −9 M and 1×10 −12 M.
9. The method of claim 1 , wherein the antibody lacks specific binding to human GPR48 and to human leucine-rich repeat containing G-protein-coupled receptor (LGR6).
10. The method of claim 1 , wherein the monoclonal antibody lacks specific binding to leucine-rich repeat containing G-protein-coupled receptor 4 (LGR4).
11. The method of claim 1 , wherein the monoclonal antibody lacks specific binding to leucine-rich repeat containing G-protein-coupled receptor 6 (LGR6).
12. The method of claim 1 , wherein the monoclonal antibody specifically binds to murine GPR49.
13. The method of claim 1 , wherein the tumor comprises colon cancer cells.
14. The method of claim 1 , wherein the tumor comprises colon adenocarcinoma cells.
15. The method of claim 1 , wherein the tumor comprises colon cancer stem cells.
16. The method of claim 1 , wherein the tumor comprises a cancer cell comprising a mutation in a human gene represented by a gene symbol selected from the group consisting of K-Ras, PI3K, PTEN, p53, H-Ras, APC, TP53, FGFR2, VANGL2, STK11, JAK2, and RB1.